GlassScriptPhysician profile
Stella Aronova
NPI 1386979656
$8,965.66
in general payments reported to CMS, 2019-2025
44 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,811 · 2022: $1,705 · 2023: $2,890 · 2024: $1,235 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,450.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,219.94 | 2021-2025 | |
| Allergan, INC. | $691.78 | 2021-2022 | |
| Pfizer INC. | $682.42 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $419.11 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $396.05 | 2021 | |
| Lundbeck LLC | $278.95 | 2022-2025 | Vyepti |
| Ipsen Biopharmaceuticals, INC | $251.50 | 2023-2025 | Dysport |
| Scilex Pharmaceuticals INC. | $215.77 | 2021-2024 | Ztlido |
| Novartis Pharmaceuticals Corporation | $205.88 | 2021-2025 | |
| Sk Life Science, INC. | $188.95 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $175.62 | 2022-2024 | Ingrezza, Ongentys |
| Harmony Biosciences LLC | $168.13 | 2022-2024 | Wakix |
| Lilly USA, LLC | $151.11 | 2022-2025 | Reyvow, Emgality, Zepbound |
| Amylyx Pharmaceuticals, INC. | $126.83 | 2023-2024 | Relyvrio |
| Ucb, INC. | $126.65 | 2022-2024 | Rystiggo, Briviact |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $119.12 | 2022-2024 | Ultomiris |
| Currax Pharmaceuticals LLC | $115.31 | 2021-2025 | Contrave |
| Merz Pharmaceuticals, LLC | $113.45 | 2021-2025 | Inbrija, Xeomin |
| Takeda Pharmaceuticals U.S.A., INC. | $112.82 | 2023-2024 | Hyqvia |
| Teva Pharmaceuticals USA, INC. | $103.21 | 2021-2025 | Austedo Xr |
| Almatica Pharma LLC | $96.64 | 2022-2023 | Gralise |
| Tanabe Pharma America, INC. | $90.71 | 2022-2024 | |
| Amneal Pharmaceuticals LLC | $88.70 | 2022-2024 | Rytary |
| Argenx US, INC. | $83.69 | 2022-2023 | Vyvgart, Vyvgart Hytrulo |
| Grifols USA, LLC | $82.01 | 2022-2023 | Gamunex-C |
| Abbott Laboratories | $80.02 | 2021 | |
| Amgen INC. | $69.29 | 2022 | |
| Genzyme Corporation | $68.66 | 2021-2023 | |
| Upsher-Smith Laboratories LLC | $54.38 | 2022 | |
| Corium, LLC | $50.63 | 2022-2023 | Adlarity |
| Protega Pharmaceutials INC | $47.73 | 2024 | Roxybond |
| Neurelis, INC. | $43.75 | 2021 | |
| Csl Behring | $37.47 | 2022-2023 | Hizentra |
| Idorsia Pharmaceuticals US INC | $32.00 | 2022-2023 | Quviviq |
| Kyowa Kirin, INC. | $28.30 | 2023 | Nourianz |
| Emd Serono, INC. | $19.15 | 2022 | |
| Acadia Pharmaceuticals INC | $19.02 | 2025 | Nuplazid |
| Averitas Pharma INC. | $17.35 | 2023 | Qutenza |
| Merz North America, INC. | $17.10 | 2025 | |
| Biogen, INC. | $16.42 | 2023 | Vumerity |
| Alnylam Pharmaceuticals INC. | $15.76 | 2023 | Amvuttra |
| Impel Pharmaceuticals INC. | $15.64 | 2023 | Trudhesa |
| Boston Scientific Corporation | $14.54 | 2022 | |
| Merck Sharp & Dohme LLC | $14.10 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stella Aronova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.